Berkshire Hathaway is putting in $10 billion through a private placement, with the rest coming from underwritten offerings and an at-the-market program
Berkshire Hathaway is putting in $10 billion through a private placement, with the rest coming from underwritten offerings and an at-the-market program
Forbright Inc. , a financial services platform that focuses on middle-market lending and digital consumer banking, is seeking to raise as much as $158 million in an US initial public offering. The Chevy Chase, Maryland-based company plans to market 7.9 million shares for $18 to $20 each, according to its filing Tuesday with the US Securities and Exchange Commission. At the top of that range, Forbr...
Forbright Inc. , a financial services platform that focuses on middle-market lending and digital consumer banking, is seeking to raise as much as $158 million in an US initial public offering. The Chevy Chase, Maryland-based company plans to market 7.9 million shares for $18 to $20 each, according to its filing Tuesday with the US Securities and Exchange Commission. At the top of that range, Forbright would have a market value of around $994 million based on the outstanding shares listed in its filing. The firm had adjusted total revenue of $77.5 million for the quarter through March, compared with $71.7 million a year earlier, the filing shows. Total deposits were $7.14 billion as of March 31, compared to $5.76 billion a year earlier. For the latest news on equity capital markets activity in the US, Canada and Latin America, terminal users can follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . Founded in 2003 as a commercial bank chartered by the Maryland under the name Congressional Bank, the company saw growth starting in 2020 when former politician John Delaney returned to the company, the filing shows. The company has grown consolidated assets to $7.9 billion at the end of 2025 from $1.9 billion in 2020. Delaney is chairman and chief executive officer and served as a member of the US House of Representatives from 2013 to 2019. Goldman Sachs Group Inc. , JPMorgan Chase & Co. and Barclays Plc are leading the offering. The shares are expected to trade on the Nasdaq Global Select Market under the symbol FRBT.
Frank Brennan IBM ( IBM ) was in focus on Tuesday as Wedbush Securities upped its price target on the IT giant, stating it sees “incremental positives” from artificial intelligence. Shares fell 3.8% in premarket trading. “Based on our recent checks, IBM continues to see solid momentum across its portfolio of products for AI, hybrid cloud, automation, and cybersecurity with customers looking for tr...
Frank Brennan IBM ( IBM ) was in focus on Tuesday as Wedbush Securities upped its price target on the IT giant, stating it sees “incremental positives” from artificial intelligence. Shares fell 3.8% in premarket trading. “Based on our recent checks, IBM continues to see solid momentum across its portfolio of products for AI, hybrid cloud, automation, and cybersecurity with customers looking for trusted, scalable and compliant solutions that can be deployed across complex environments. IBM’s ability to combine software, consulting, and infrastructure into one integrated stack remains an important advantage to the company’s business flywheel as more organizations launch production-scale AI use cases,” analysts at the firm wrote in a note to clients. “We believe that IBM’s focus on building out its data moat, including its $11 billion acquisition of Confluent, is a strategic move with enterprises looking to get more from their existing data environments while adding data processing capabilities across its hybrid cloud ecosystem as IBM looks to provide end-to-end integrations across applications, analytics, data systems, and AI agents. IBM has also seen $4.5 billion in productivity gains thus far, without counting savings from IBM Bob, as the company continues to focus on internal investments to drive operating leverage at scale.” The analysts raised their price target on IBM to $350 from $320 and reiterated their Outperform rating. The increased price target comes after IBM shares gained more than 7% on Monday due to an old message from President Trump that recirculated online and Barclays initiated coverage on the stock with an Overweight rating. In addition to the aforementioned AI-linked positives, the analysts also noted that IBM's positioning in quantum computing still appears “underappreciated” by investors. “The company is in the early innings of unlocking benefits at the crossroads of AI and quantum with IBM stating that quantum advantage will be reached this y...
Intel 's (NASDAQ: INTC) shares have soared 489%, and Micron Technology (NASDAQ: MU) stock is up a shocking 869% over the past year. The artificial intelligence spending boom that's currently underway is fueling interest in these stocks, and both could benefit from rising semiconductor demand in the coming years. But which is the better AI stock to buy right now? Image source: Getty Images. Continu...
Intel 's (NASDAQ: INTC) shares have soared 489%, and Micron Technology (NASDAQ: MU) stock is up a shocking 869% over the past year. The artificial intelligence spending boom that's currently underway is fueling interest in these stocks, and both could benefit from rising semiconductor demand in the coming years. But which is the better AI stock to buy right now? Image source: Getty Images. Continue reading
Mobia Medical could more than double as it makes inroads in an underserved corner of the stroke recovery market, according to Goldman Sachs. The investment bank initiated coverage of the neurostimulation therapy developer with a buy rating. It also put a $31 price target on shares, implying 130% upside from Monday's close. "Based on the company's innovative neuro-stimulation technology, large mark...
Mobia Medical could more than double as it makes inroads in an underserved corner of the stroke recovery market, according to Goldman Sachs. The investment bank initiated coverage of the neurostimulation therapy developer with a buy rating. It also put a $31 price target on shares, implying 130% upside from Monday's close. "Based on the company's innovative neuro-stimulation technology, large market opportunity, performance of prior market creation [small- and mid-capitalization] MedTech comps, and … projected revenue trajectory, we view the stock emerging as a differentiated growth asset," analyst David Roman said in a note to clients. Mobia went public on the Nasdaq on May 8, pricing its stock at $15. Goldman Sachs served as an underwriter of the IPO, alongside Bank of America Securities and JPMorgan. Shares closed at $13.50 on Monday, though they rallied 9% Tuesday on the back of Goldman's bullish call. MOBI 1M mountain Mobia Medical stock is up roughly 15% since its public market debut in early May. Mobia has developed an implantable vagus nerve stimulation system called Vivistim that, when paired with rehabilitation therapy, promotes chronic stroke recovery. Vivistim could serve roughly 1 million patients in the U.S., capturing a considerable part of the stroke market, per Goldman Sachs. "We expect significant penetration given the (1) high unmet need; (2) limited alternative or competitive therapies; and (3) highly motivated patient base," Roman wrote. Each year, roughly 800,000 strokes occur in the U.S., and that figure is likely to grow as the American population continues to age, according to the analyst. In addition, more than half of stroke sufferers have mobility limitations or other vital function issues.
JHVEPhoto/iStock Editorial via Getty Images Introduction Zoetis ( ZTS ) is a company I've yet to cover here on Seeking Alpha. Although the business isn't really my style, I couldn't help but be drawn to the 53% drop in share price in the past year. Plus, the company pays a dividend and has a solid, near 3% dividend yield. Also, I believe the steep drop in price improves the long-term setup and mak...
JHVEPhoto/iStock Editorial via Getty Images Introduction Zoetis ( ZTS ) is a company I've yet to cover here on Seeking Alpha. Although the business isn't really my style, I couldn't help but be drawn to the 53% drop in share price in the past year. Plus, the company pays a dividend and has a solid, near 3% dividend yield. Also, I believe the steep drop in price improves the long-term setup and makes them interesting for long-term income investors. In this article, I discuss their latest earnings, why I think the stock has underperformed, and why, despite my hold rating, I think the stock is becoming increasingly attractive for long-term dividend growth investors. Brief Overview Zoetis is currently the world's largest animal health company. Spun off from Pfizer ( PFE ) over a decade ago, ZTS has grown into a major player in the animal healthcare space. They operate in two major segments: Companion Animals Livestock Their Companion Animals segment is their largest contributor to revenue, accounting for 79% of revenue in 2025. This segment includes dogs, cats, and horses and remains the company's primary growth driver. Their livestock segment includes cattle, sheep, fish, and swine. They have seven product categories and operate both in the U.S. and internationally. They focus on the discovery, development, manufacturing, and commercialization of animal medications, vaccines, diagnostic products & services, and genetic testing. Severe Underperformance As previously mentioned, ZTS is down more than 50% in the past year and 54% in the past 5 years. In my opinion, part of their underperformance stems from their elevated post-pandemic valuation that has since compressed as growth has seemed to normalize. Seeking Alpha Over the past year, persistent inflation and weaker discretionary consumer spending have pressured the business. In their most recent quarter at the beginning of May, headwinds persisted, resulting in a pullback in price as management was forced to revise gui...
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax'...
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose and 51.3% for the 50 mg dose, versus 10.4% for placebo, implying placebo-adjusted remission rates of about 39% to 40% and highly statistically significant results. The problem for the stock was not efficacy, but safety optics... Goldman analyst Esah Hayat pointed out that the market was focused not on efficacy but on cancer cases among patients taking the higher doses of obefazimod: ABTECT maintenance trial out yday ( press release ) – "at week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)." Though no new safety signals were observed per the press release, the safety results summary table (below) indicated 8 cases of malignancy , which spooked the market . Note, a number of investors are in this name for the M&A takeout story which could be muddied on this update. Mgmt did host a call on the results in which they did suggest the malignancies observed do align with background rates in UC (e.g. here for basal cell carcinoma), and weren't considered a new safety signal by monitoring committees. Wonder if this becomes a Fenebrutinib-like situation where market goes negative on headline safety imbalance, those are explained away as non-treatment linked at a detailed presentation and docs come out in support of...
Scotland great, 75, mistakenly posted on social media ‘Treatment is going well’ says former player and manager Sir Kenny Dalglish has revealed he is receiving treatment for cancer. The Liverpool legend, who is 75, confirmed the diagnosis on Tuesday having mistakenly posted about his treatment earlier in the day. Liverpool have said: “The support, best wishes and love of everyone at Liverpool FC ar...
Scotland great, 75, mistakenly posted on social media ‘Treatment is going well’ says former player and manager Sir Kenny Dalglish has revealed he is receiving treatment for cancer. The Liverpool legend, who is 75, confirmed the diagnosis on Tuesday having mistakenly posted about his treatment earlier in the day. Liverpool have said: “The support, best wishes and love of everyone at Liverpool FC are, and will be, with Sir Kenny and his family.” Dalglish wrote: “As my inadvertent social media post has indicated, I am currently undergoing treatment for cancer. Unlike my mobile phone use, the treatment is going well. Ideally, this would have remained private because that’s the way it should be, but my useless technology skills have forced my hand. Continue reading...
Wall Street has been practically holding its breath waiting for Berkshire Hathaway 's (NYSE:BRKA) (NYSE:BRKB) new CEO to make his first big move. It is important because Greg Abel only took over the top spot at the $1 trillion market cap conglomerate from Warren Buffett at the start of 2026. The day has finally come: Berkshire just announced it is paying $6.8 billion to acquire Taylor Morrison Hom...
Wall Street has been practically holding its breath waiting for Berkshire Hathaway 's (NYSE:BRKA) (NYSE:BRKB) new CEO to make his first big move. It is important because Greg Abel only took over the top spot at the $1 trillion market cap conglomerate from Warren Buffett at the start of 2026. The day has finally come: Berkshire just announced it is paying $6.8 billion to acquire Taylor Morrison Home (NYSE:TMHC) . What should investors make of the deal? During his first quarter at the helm of Berkshire Hathaway, Abel allowed cash to pile up on the company's balance sheet. That was, basically, the same thing that Warren Buffett was doing in the years leading up to his retirement. At the end of the first quarter of 2026, Berkshire's cash balance stood at a gargantuan $397 billion. Image source: Getty Images. Continue reading
Black Rifle Coffee ( BRCC ) has received notification from the New York Stock Exchange (NYSE) that it is now in compliance with the minimum share price requirement. Previously, on February 11, 2026, the NYSE informed the company that it was non-compliant because its Class A common stock average closing price was under $1.00 for a 30 trading-day period. On June 1, 2026, the NYSE confirmed that as o...
Black Rifle Coffee ( BRCC ) has received notification from the New York Stock Exchange (NYSE) that it is now in compliance with the minimum share price requirement. Previously, on February 11, 2026, the NYSE informed the company that it was non-compliant because its Class A common stock average closing price was under $1.00 for a 30 trading-day period. On June 1, 2026, the NYSE confirmed that as of May 29, 2026, the company regained compliance as its Class A common stock closed at least $1.00 on that date and maintained an average closing price of at least $1.00 over the past 30 trading days. Thus, the company is no longer below the minimum share price standard. This compliance was achieved without executing a reverse stock split that had been approved by stockholders on May 28, 2026. The company's Class A common stock will remain listed and traded on the NYSE, provided it continues to meet all listing standards, the company said in a statement. More on BRCC BRC Inc. 2026 Q1 - Results - Earnings Call Presentation BRC Inc. (BRCC) Q1 2026 Earnings Call Transcript BRC: Coffee Price Stabilization And Stronger Retail Distribution (Upgrade) Black Rifle Coffee regains NYSE compliance after share price improvement BRC outlines 2026 outlook of at least 8% revenue growth and about $29M adjusted EBITDA